KRYS vs FOLD vs RARE vs RCKT

For growth investors, Krystal Biotech, Inc.

(KRYS) is the stronger pick with 33. 9% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Krystal Biotech, Inc. (KRYS) offers the better valuation at 42. 2x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate Krystal Biotech, Inc. (KRYS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Krystal Biotech, Inc.

is actually cheaper at 38. 3x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +310. 3%, compared to -91. 1% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: KRYS returned +26. 2% versus RCKT's -90. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 63β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 125% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Krystal Biotech, Inc.

(KRYS) is pulling ahead at 33. 9% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Krystal Biotech, Inc.

(KRYS) trades at 38. 3x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 2. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 98. 6% to $51. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +125. 0% 10Y return). Both have compounded well over 10 years (FOLD: +125. 0%, RARE: -58. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KRYS is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; RARE is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.